Diabetic Vasculopathy Antibodies

About Angios Biotech

Angios Biotech is a private, pre-clinical stage biotech firm developing innovative vascular disease treatments and research tools. Its core asset is a proprietary, patented platform that generates human blood vessel organoids from iPSCs, aiming to overcome the limitations of animal models. The company is advancing antibody therapeutics for diabetic complications in partnership with Abcellera, developing vascular transplants, and commercializing its organoid platform for drug screening. With a lean, science-driven team based in Austria and operations in the US and Canada, Angios is positioning itself at the intersection of vascular biology, regenerative medicine, and animal-free testing.

Therapeutic Areas